Lund University Hospital

sus.se

Total trials

65

Active

15

Phase 3

10

Total enrollment

12,193

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 9 of 9 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
177Lu-DOTATOC1
Capecitabine1
epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab1
epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab1
Pemigatinib1
Retifanlimab1
Fluorouracil1
Oxaliplatin1
Irinotecan1

Next readouts

  • 2026-10-01
  • 2026-11-30
  • 2027-12-31
  • 2035-09

Top conditions

  • Breast Cancer3
  • Colorectal Cancer3
  • Cardiovascular Diseases2
  • Liver Metastases2
  • Opioid Use2
  • Neuroendocrine Tumors2
  • Head and Neck Neoplasms2
  • Radiotherapy; Complications2

Frequently asked questions about Lund University Hospital

How many clinical trials does Lund University Hospital have on ClinicalTrials.gov?
Lund University Hospital is listed as the lead sponsor on 65 clinical trials in ClinicalTrials.gov, 15 of which are currently active (recruiting, enrolling, or ongoing).
How many of Lund University Hospital's trials are in Phase 3?
10 of Lund University Hospital's trials are in Phase 3, spread across 9 active drug programs.
What therapeutic areas does Lund University Hospital focus on?
Lund University Hospital's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Colorectal Cancer, Cardiovascular Diseases, Liver Metastases, Opioid Use.
When are Lund University Hospital's next clinical trial readouts?
Lund University Hospital has 4 upcoming primary-completion readouts tracked here; the soonest is “Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.”, expected around 2026-10-01.